CytomX Therapeutics Inc (NAS:CTMX)
$ 1.02 -0.12 (-10.53%) Market Cap: 79.82 Mil Enterprise Value: -17.78 Mil PE Ratio: 6.00 PB Ratio: 0 GF Score: 57/100

CytomX Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 12, 2019 / 09:40PM GMT
Release Date Price: $9.92 (-0.70%)
Terence C. Flynn
Goldman Sachs Group Inc., Research Division - MD

Okay. Great. Thanks for joining us, everyone. I'm Terence Flynn, one of the biotech analysts here at Goldman. And we're very pleased to have CytomX. Joining us from the company is Sean McCarthy, CEO. Sean, I'm going to turn it over to you for some opening remarks before we launch into questions.

Sean A. McCarthy
CytomX Therapeutics, Inc. - Chairman, CEO & President

Great. Thanks, Terence. Pleasure to be here. It's been a great couple of days. So we set out several years ago to reimagine therapeutic antibodies for the treatment of various diseases actually in the early incarnation of the company. Over the last 4 or 5 years, we focused on oncology, which is an obvious application for what we do. And this reimagination process is really focused on a very unique platform that we call Probodies. Probodies are therapeutic antibodies that are designed to be localized into disease tissue, so into cancer tissue and really to fundamentally alter the distribution of an active antibody in a patient.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot